Skip to content

Study · Case report or series · n = 1 · 2023

2 results

Rhabdomyolysis Associated With Semaglutide Therapy: A Case Report.

Billings SA, Felix HM, Prier CC, Hedges MS

Cureus9 Dec 2023Cited by 5 (Europe PMC)

PMID38192938 (opens in a new tab)PMCIDPMC10773591 (opens in a new tab)DOI10.7759/cureus.50227 (opens in a new tab)PepBankPUB-38192938
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

This report describes the case of a 47-year-old woman with myalgias, weakness, and elevated creatine kinase associated with semaglutide therapy prescribed for weight loss. Her symptoms and laboratory markers were consistent with rhabdomyolysis and resolved after discontinuation of semaglutide. Upon rechallenge at a lower dose, symptoms recurred, and urinalysis was consistent with myoglobinuria. Symptoms again rapidly resolved upon discontinuation of the medication. It is imperative for physicians to recognize semaglutide as a possible cause of myalgias and rhabdomyolysis in clinically suspected patients. To the best of our knowledge, this is the first reported case in the literature and may be specific to semaglutide rather than a class effect of glucagon-like peptide 1 (GLP-1) agonists.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 47-year-old woman taking semaglutide for weight loss, rhabdomyolysis with myalgias, weakness and raised creatine kinase developed and resolved after semaglutide was stopped.

    In plain wordsIn one woman taking semaglutide for weight loss, muscle breakdown developed and went away after the drug was stopped.

    Peptide
    Semaglutide
    Outcome
    IncreaseRhabdomyolysis during semaglutide therapy
    Study

    n = 1

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Her symptoms and laboratory markers were consistent with rhabdomyolysis and resolved after discontinuation of semaglutide.
    1 context sentence
    Summary · context
    This report describes the case of a 47-year-old woman with myalgias, weakness, and elevated creatine kinase associated with semaglutide therapy prescribed for weight loss.
  2. 02HumanCase report or seriesSafety outcome

    In the same woman, rechallenge with a lower dose of semaglutide caused the symptoms to recur with myoglobinuria, and they resolved again after discontinuation.

    In plain wordsIn this one woman, symptoms came back when she restarted semaglutide at a lower dose and went away again after stopping.

    Peptide
    Semaglutide
    Outcome
    IncreaseRecurrence of rhabdomyolysis on rechallenge
    Study

    n = 1

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon rechallenge at a lower dose, symptoms recurred, and urinalysis was consistent with myoglobinuria. Symptoms again rapidly resolved upon discontinuation of the medication.
    1 context sentence
    Summary · context
    This report describes the case of a 47-year-old woman with myalgias, weakness, and elevated creatine kinase associated with semaglutide therapy prescribed for weight loss.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.